nalbuphine HCl ER

Phase 2/3Completed

1 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis, Nodularis Prurigo, Prurigo

Trial Timeline

Aug 15, 2015 → Sep 3, 2017

NCT ID

NCT02174432

About nalbuphine HCl ER

nalbuphine HCl ER is a phase 2/3 stage product being developed by Trevi Therapeutics for Prurigo Nodularis. The current trial status is completed. This product is registered under clinical trial identifier NCT02174432. Target conditions include Prurigo Nodularis, Nodularis Prurigo, Prurigo.

What happened to similar drugs?

1 of 7 similar drugs in Prurigo Nodularis were approved

Approved (1) Terminated (0) Active (6)

✅UpadacitinibAbbVieApproved

🔄Rocatinlimab + PlaceboAmgenPhase 3

🔄DupilumabSanofiPhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

🔄Povorcitinib + PlaceboIncytePhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02174432	Phase 2/3	Completed	Aug 15, 2015	Sep 3, 2017	Prurigo Nodularis
NCT02143973	Phase 2/3	Completed	Sep 1, 2014	Jan 1, 2016	Uremic Pruritus
NCT02373215	Phase 1	Completed	Apr 1, 2013	Nov 1, 2013	Uremic Pruritus

Competing Products

20 competing products in Prurigo Nodularis

See all competitors

Product	Company	Stage	Hype Score
Vixarelimab + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
Upadacitinib	AbbVie	Approved	50
Pimecrolimus + Hydrocortisone + Pimecrolimus	Novartis	Phase 2	35
Rocatinlimab + Placebo	Amgen	Phase 3	44
Abrocitinib	Pfizer	Phase 2	35
Dupilumab SAR231893 (REGN668)	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Phase 3	47
Dupilumab	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Pre-clinical	30
Ruxolitinib Cream 1.5%	Incyte	Phase 1	26
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
INCB054707 + Placebo	Incyte	Phase 2	32
Povorcitinib + Placebo	Incyte	Phase 3	44
Povorcitinib + Placebo	Incyte	Phase 3	44
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
CDX-0159 + Normal saline	Celldex Therapeutics	Phase 1	23
barzolvolimab	Celldex Therapeutics	Phase 2	33
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID	Trevi Therapeutics	Phase 2/3	32
Nalbuphine ER Tablets + Placebo Tablets	Trevi Therapeutics	Phase 2/3	32
serlopitant + Placebo	Vyne Therapeutics	Phase 2	25